10200-43-8

Basic information

• Product Name: 2-methyl oxazole 4-ethyl ester
• Synonyms: ETHYL-4-METHYL-3,5-OXAZOLECARBOXYLATE;2-methyl oxazole 4-ethyl ester;2-Methyl-4-oxazolecarboxylic acid ethyl ester;Ethyl 2-methyl-4-oxazolecarboxylate;4-(Ethoxycarbonyl)-2-methyl-1,3-oxazole;Ethyl 2-methyl-1,3-oxazole-4-carboxylate;2-Methyl-oxazole-4-carboxylic acid ethyl ester
• CAS NO: 10200-43-8
• Molecular Formula: C₇H₉NO₃
• Molecular Weight: 155.15
• Mol File: 10200-43-8.mol

Chemical Properties

• Boiling Point: 210.361 °C at 760 mmHg
• Flash Point: 81.023 °C
• Appearance: /
• Density: 1.14 g/cm³
• Vapor Pressure: 0.193mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-methyl oxazole 4-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl oxazole 4-ethyl ester(10200-43-8)
• EPA Substance Registry System: 2-methyl oxazole 4-ethyl ester(10200-43-8)

Safety Data

• Hazardous Substances Data: 10200-43-8(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C7H9NO3/c1-3-10-7(9)6-4-11-5(2)8-6/h4H,3H2,1-2H3

Upstream product

• 109-94-4 formic acid ethyl ester 
• 60-35-5 acetamide 
• 617-35-6 2-oxo-propionic acid ethyl ester 
• 74-88-4 methyl iodide 
• 70-23-5 ethyl Bromopyruvate 
• 23012-14-8 oxazole-4-carboxylic acid ethyl ester 
• 142-71-2 copper diacetate 
• 68683-04-5 ethyl (2-methyl-2-oxazolin-4-yl)carboxylate 
• 7787-70-4 copper(I) bromide 
• 108-24-7 acetic anhydride 
• 61999-29-9 2-Methyl-4,5-dihydro-1,3-oxazole-4-carboxylic acid ethyl ester 
• 14762-48-2 ethyl 2-diazo-3-oxo-propanoate 
• 75-05-8 acetonitrile 

Downstream Products

• 113732-84-6 2-methyl-1,3-oxazole-4-carbaldehyde 
• 141567-53-5 4-hydroxymethyl-2-methyloxazole 
• 875553-59-6 N-methoxy-N-methyl-2-methyloxazole-4-carboxamide 
• 100872-45-5 4-[4-(4-methoxy-phenyl)-thiazol-2-yl]-2-methyl-oxazole 
• 96461-28-8 2-methyl-4-[4-(4-nitro-phenyl)-thiazol-2-yl]-oxazole 
• 96462-75-8 4-[4-(4-bromo-phenyl)-thiazol-2-yl]-2-methyl-oxazole 
• 96583-11-8 4-[4-(4-chloro-phenyl)-thiazol-2-yl]-2-methyl-oxazole 
• 100872-18-2 2-methyl-4-(4-p-tolyl-thiazol-2-yl)-oxazole 
• 106166-86-3 2-methyl-4-(4-phenyl-thiazol-2-yl)-oxazole 
• 90980-10-2 2-methyl-oxazole-4-carbothioic acid amide 
• 89282-09-7 2-methyl-4-oxazolecarbonitrile 
• 139631-17-7 (2S,4S,5S,7E,9E,11E)-4-((tert-Butyldiphenylsilyl)oxy)-1,2-(isopropylidenedioxy)-5,7,11-trimethyl-12-(2'-methyloxazol-4'-yl)-7,9,11-dodecatrien-6-one 
• 139631-17-7 (5Z,7E,9E)-(2S,3S)-2-(tert-Butyl-diphenyl-silanyloxy)-1-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-3,5,9-trimethyl-10-(2-methyl-oxazol-4-yl)-deca-5,7,9-trien-4-one 
• 139630-91-4 (E)-2-methyl-3-(2-methyloxazol-4-yl)acrylaldehyde 

Relevant articles and documents

DIRECT PREPARATION OF 4-CARBOETHOXY-1,3-OXAZOLES

The diazoaldehyde ester N2C(CHO)CO2Et undergoes rhodium-catalyzed reaction with nitriles to give 4-carboethoxy-1,3-oxazoles directly.

Facile synthesis of oxazoles starting from ketones

A new and efficient method for the preparation of 2,4- and 2,4,5-substituted oxazoles is described which is based upon the reaction of α-sulfonyloxy ketone intermediates with acetamide or benzamide.

An efficient preparation of 2-alkyl-oxazoles from 2-iodooxazoles

An efficient synthesis toward 2-alkyl substituted oxazoles has been achieved through Suzuki cross-coupling reaction. Treatment of various alkyl iodides with 9-MeO-BBN, followed by in situ palladium-catalyzed carbon-carbon formation with 2-iodooxazoles obt

Direct palladium-catalyzed alkenylation, benzylation and alkylation of ethyl oxazole-4-carboxylate with alkenyl-, benzyl- and alkyl halides

The ethyl oxazole-4-carboxylate was directly and regioselectively alkenylated, benzylated and alkylated with alkenyl-, benzyl-, allyl- and alkyl halides in the presence of catalytic amounts of palladium acetate with caesium carbonate using Buchwald's John

Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro- (7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABAAα5 benzodiazepine binding site

The identification of a novel series of 7,8,9,10-tetrahydro-(7,10-ethano)- 1,2,4-triazolo[3,4-a]phthalazines as GABAAα5 inverse agonists, which have both binding and functional (efficacy) selectivity for the benzodiazepine binding site of α5- over α1-, α2-, and α3-containing GABAA receptor subtypes, is described. Binding selectivity was determined to a large part by the degree of planarity of the fused ring system whereas functional selectivity was dependent on the nature of the heterocycle at the 3-position of the triazolopyridazine ring. 3-Furan and 5-methylisoxazole were shown to be optimal for GABAAα5 functional selectvity. 3-(5-Methylisoxazol-3-yl)-6-(2-pyridyl)methyloxy-1,2,4- triazolo[3,4-a]phthalazine (43) was identified as a full inverse agonist at the GABAAα5 subtype with functional selectivity over the other GABAA receptor subtypes and good oral bioavailability.

BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

Compounds of the general formula (I): or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R1 is a 5- to 6-membered aromatic ring which bears a substituent represented by the general formula: R-Z1-X-Z2- (wherein R1 is hydrogen or optionally substituted hydrocarbyl; X is optionally substituted alkylene; and Z1 and Z2 are each a heteroatom) and may be further substituted, with R being optionally bonded to the aromatic ring to form another ring; Y is optionally substituted imino; and R2 and R3 are each optionally substituted aliphatic hydrocarbyl or an optionally substituted hetero-alicyclic group.

Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions

The present invention relates to novel atropisomers of 3-heteroaryl-4(3H)-quinazolinones of the formula Ia, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.

Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists

The present invention relates to novel atropisomers of 2-(aryl or heteroaryl)-3-aryl-4(3H)-quinazolinones of the formula I, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trau

Towards a total synthesis of ulapualide A. Concise synthetic routes to the tris-oxazole ring system and tris-oxazole macrolide core in ulapualides, kabiramides, halichondramides, mycalolides and halishigamides

A range of methods for the synthesis of mono-, bis- and tris-2,4-disubstituted oxazoles were evaluated, which led ultimately to a concise synthesis of the three contiguous oxazole ring system 26 in the ulapualide family of 25-membered macrolides, e.g. 1, found in marine organisms. The tris-oxazole macrolide core 30 in ulapualide A (1) was also synthesised based on a macrolactamisation strategy from the two functionalised mono-oxazole precursors 28 and 29, followed by oxazoline 45 and oxazole ring formation, exploiting the methodologies established in the synthesis of linear bis- and tris-oxazoles in the formation of 18 and 26. The tris-oxazole 26 was converted into the corresponding phosphonium salt 5 in readiness for elaboration to ulapualide A (1). The Royal Society of Chemistry 2000.

Rhizoxin synthetic studies. 2. Synthesis of the left hand [C(10) to C(19)] and polyene fragments

The syntheses of the central core and the polyene fragments of the antitumor macrolide rhizoxin have been achieved in an efficient manner. The core has been prepared in enantiopure form via a asymmetric allylation/aldol protocol. The selective oxidation o